Drug interactions
Baricitinib + Tisagenlecleucel
Severity: Major
Baricitinib and Tisagenlecleucel: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Baricitinib may impair CAR T-cell expansion and activity, possibly reducing efficacy. It also adds to the infection risk that follows lymphodepletion and CAR T therapy.
What this interaction means in plain words
Baricitinib and Tisagenlecleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Baricitinib belongs to Musculoskeletal; Tisagenlecleucel belongs to Oncology.
Why it happens
JAK inhibition suppresses T-cell activation and cytokine signaling, adding to immunosuppression and potentially limiting CAR T activity.
What to do
Avoid baricitinib around leukapheresis and CAR T infusion unless clearly needed. Coordinate with the oncology team and monitor for infection.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Baricitinib and Tisagenlecleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Baricitinib
- Adenovirus types 4 and 7 live + Baricitinib Contraindicated
- Baricitinib + Bcg vaccine live Contraindicated
- Baricitinib + Tofacitinib Contraindicated
- Baricitinib + Upadacitinib Contraindicated
- Abatacept + Baricitinib Major
- Adalimumab + Baricitinib Major
Other interactions of Tisagenlecleucel
Frequently asked questions
Can I take Baricitinib with Tisagenlecleucel?
MediHelp rates the interaction as major. Baricitinib and Tisagenlecleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Baricitinib may impair CAR T-cell expansion and activity, possibly reducing efficacy. It also adds to the infection risk that follows lymphodepletion and CAR T therapy.
How serious is the interaction between Baricitinib and Tisagenlecleucel?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid baricitinib around leukapheresis and CAR T infusion unless clearly needed. Coordinate with the oncology team and monitor for infection.
What other medicines interact with Baricitinib?
MediHelp also lists interactions of Baricitinib with, for example, Adenovirus types 4 and 7 live, Bcg vaccine live, Tofacitinib. The full list is on the Baricitinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
